Share Price and Basic Stock Data
Last Updated: November 11, 2025, 12:15 am
| PEG Ratio | -8.87 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Glenmark Life Sciences Ltd operates in the pharmaceuticals sector, focusing on the development and manufacturing of active pharmaceutical ingredients (APIs). As of the latest reporting period, the company’s share price stood at ₹1,815, with a market capitalization of ₹51,238 Cr. The company reported total sales of ₹12,990 Cr for the financial year ending March 2023, with a trailing twelve-month (TTM) sales figure of ₹13,342 Cr. Quarterly sales showed fluctuations, with the highest quarterly sales recorded at ₹3,434 Cr in September 2024. This indicates a steady growth trajectory, albeit with some volatility as seen in the subsequent quarters. The company’s operational performance is reflected in its operating profit margin (OPM), which averaged around 18% for the financial year 2025, aligning closely with industry expectations for pharmaceutical manufacturers.
Profitability and Efficiency Metrics
Glenmark Life Sciences reported a net profit of ₹754 Cr for the financial year 2025, with a notable return on equity (ROE) of 15.8% and a return on capital employed (ROCE) of 19.4%. These figures demonstrate a solid profitability framework, especially when compared to the sector averages, which typically hover around 12-15% for ROE. However, the company faced challenges in certain quarters, notably recording a net loss of ₹1,214 Cr in March 2024, which highlighted a period of operational strain. The interest coverage ratio (ICR) stood at a robust 11.90x, indicating strong capacity to meet interest obligations, while the cash conversion cycle (CCC) was reported at 129 days, reflecting a moderate efficiency in managing working capital. The OPM varied significantly, particularly dipping to -8% in December 2023, which raises concerns regarding cost management during that period.
Balance Sheet Strength and Financial Ratios
The balance sheet of Glenmark Life Sciences shows a healthy reserve position, with total reserves reported at ₹8,821 Cr as of March 2025, against borrowings of ₹2,473 Cr, indicating a low debt-to-equity ratio of 0.24. This low leverage ratio suggests that the company is not overly reliant on debt, which mitigates financial risk. Furthermore, the company reported a book value per share of ₹313.60, which stands in contrast to its price-to-book value ratio of 4.91x, indicating that the stock is trading at a premium to its book value. The current ratio of 1.56x and quick ratio of 1.05x reflect adequate liquidity, enabling Glenmark to cover its short-term liabilities comfortably. However, the significant decline in net profit margins, which stood at 7.86% for FY 2025, compared to 8.07% the previous year, raises concerns about sustainability in profitability amidst rising costs.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Glenmark Life Sciences reflects a diverse ownership structure, with promoters holding 46.64% and foreign institutional investors (FIIs) at 20.73%. Domestic institutional investors (DIIs) accounted for 18.61%, while the public held the remaining 13.97%. The consistency in promoter holdings indicates strong management confidence in the company’s long-term prospects. However, the recent decrease in FII holdings from 23.19% in December 2022 to 20.73% in June 2025 may suggest a cautious sentiment among foreign investors. The total number of shareholders has also declined from 3,00,106 in December 2022 to 1,98,789 in June 2025, which could indicate a reduction in retail investor confidence. This trend warrants attention as it may impact the stock’s liquidity and overall market perception.
Outlook, Risks, and Final Insight
Looking ahead, Glenmark Life Sciences faces both opportunities and challenges. The company’s solid operational metrics and manageable debt levels position it favorably for future growth, especially as it seeks to capitalize on the increasing demand for pharmaceuticals. However, the volatility in quarterly earnings and the significant loss recorded in March 2024 highlight operational risks that need to be addressed. Additionally, the potential for regulatory changes in the pharmaceutical sector could impact profitability. The company must focus on enhancing operational efficiency and managing costs to sustain its margins. Furthermore, maintaining investor confidence is crucial, especially given the decline in both FII and total shareholders. Overall, while Glenmark Life Sciences has a robust foundation, it must navigate these risks to unlock its full potential in the competitive pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Glenmark Life Sciences Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 136 Cr. | 108 | 247/84.3 | 31.0 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,937 Cr. | 453 | 479/192 | 102 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.4 Cr. | 45.1 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 37.3 Cr. | 25.4 | 29.1/17.0 | 38.8 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,998.92 Cr | 1,191.15 | 55.95 | 199.13 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,777 | 3,018 | 3,100 | 3,001 | 3,036 | 3,207 | 2,507 | 3,063 | 3,244 | 3,434 | 3,388 | 3,256 | 3,264 |
| Expenses | 2,346 | 2,539 | 2,626 | 2,603 | 2,599 | 2,745 | 2,715 | 2,559 | 2,656 | 2,832 | 2,787 | 2,695 | 2,684 |
| Operating Profit | 432 | 479 | 474 | 398 | 437 | 462 | -209 | 504 | 588 | 602 | 600 | 561 | 581 |
| OPM % | 16% | 16% | 15% | 13% | 14% | 14% | -8% | 16% | 18% | 18% | 18% | 17% | 18% |
| Other Income | 183 | 86 | 209 | -696 | -32 | -205 | 87 | 351 | 31 | 39 | 31 | -361 | -297 |
| Interest | 60 | 83 | 97 | 109 | 112 | 121 | 134 | 149 | 40 | 48 | 52 | 67 | 58 |
| Depreciation | 147 | 146 | 152 | 135 | 142 | 141 | 147 | 151 | 118 | 120 | 123 | 125 | 130 |
| Profit before tax | 408 | 337 | 435 | -542 | 151 | -6 | -403 | 555 | 462 | 473 | 456 | 8 | 96 |
| Tax % | 48% | 17% | 33% | -26% | -14% | 997% | -18% | 319% | 26% | 25% | 24% | 45% | 51% |
| Net Profit | 211 | 279 | 291 | -403 | 173 | -62 | -331 | -1,214 | 340 | 354 | 348 | 4 | 47 |
| EPS in Rs | 6.82 | 9.23 | 9.66 | -15.18 | 5.31 | -2.90 | -12.45 | -43.17 | 12.06 | 12.55 | 12.33 | 0.16 | 1.66 |
Last Updated: August 19, 2025, 2:37 pm
Below is a detailed analysis of the quarterly data for Glenmark Life Sciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 3,264.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,256.00 Cr. (Mar 2025) to 3,264.00 Cr., marking an increase of 8.00 Cr..
- For Expenses, as of Jun 2025, the value is 2,684.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2,695.00 Cr. (Mar 2025) to 2,684.00 Cr., marking a decrease of 11.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 581.00 Cr.. The value appears strong and on an upward trend. It has increased from 561.00 Cr. (Mar 2025) to 581.00 Cr., marking an increase of 20.00 Cr..
- For OPM %, as of Jun 2025, the value is 18.00%. The value appears strong and on an upward trend. It has increased from 17.00% (Mar 2025) to 18.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is -297.00 Cr.. The value appears strong and on an upward trend. It has increased from -361.00 Cr. (Mar 2025) to -297.00 Cr., marking an increase of 64.00 Cr..
- For Interest, as of Jun 2025, the value is 58.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 67.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 9.00 Cr..
- For Depreciation, as of Jun 2025, the value is 130.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 125.00 Cr. (Mar 2025) to 130.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 96.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2025) to 96.00 Cr., marking an increase of 88.00 Cr..
- For Tax %, as of Jun 2025, the value is 51.00%. The value appears to be increasing, which may not be favorable. It has increased from 45.00% (Mar 2025) to 51.00%, marking an increase of 6.00%.
- For Net Profit, as of Jun 2025, the value is 47.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 47.00 Cr., marking an increase of 43.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.66. The value appears strong and on an upward trend. It has increased from 0.16 (Mar 2025) to 1.66, marking an increase of 1.50.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:15 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,005 | 6,563 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 12,990 | 11,813 | 13,322 | 13,342 |
| Expenses | 4,914 | 5,348 | 6,125 | 7,043 | 7,457 | 8,280 | 8,942 | 8,860 | 9,978 | 10,712 | 10,618 | 10,970 | 10,998 |
| Operating Profit | 1,091 | 1,214 | 1,437 | 2,037 | 1,617 | 1,586 | 1,699 | 2,084 | 2,327 | 2,278 | 1,195 | 2,351 | 2,344 |
| OPM % | 18% | 18% | 19% | 22% | 18% | 16% | 16% | 19% | 19% | 18% | 10% | 18% | 18% |
| Other Income | 11 | -180 | 20 | -44 | 89 | 375 | 191 | 95 | -101 | -449 | 336 | -259 | -587 |
| Interest | 189 | 190 | 179 | 237 | 286 | 335 | 377 | 353 | 298 | 350 | 516 | 207 | 226 |
| Depreciation | 217 | 300 | 234 | 264 | 302 | 326 | 417 | 444 | 487 | 611 | 582 | 486 | 498 |
| Profit before tax | 697 | 544 | 1,044 | 1,491 | 1,119 | 1,301 | 1,096 | 1,382 | 1,441 | 868 | 434 | 1,399 | 1,032 |
| Tax % | 22% | 61% | 29% | 26% | 28% | 29% | 29% | 30% | 31% | 57% | 430% | 25% | |
| Net Profit | 546 | 209 | 743 | 1,109 | 804 | 925 | 776 | 970 | 994 | 377 | -1,434 | 1,047 | 754 |
| EPS in Rs | 19.99 | 7.72 | 26.33 | 39.29 | 28.49 | 32.78 | 27.50 | 34.38 | 33.37 | 10.53 | -53.22 | 37.11 | 26.70 |
| Dividend Payout % | 0% | 26% | 8% | 5% | 7% | 6% | 9% | 7% | 7% | 24% | -5% | 7% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -61.72% | 255.50% | 49.26% | -27.50% | 15.05% | -16.11% | 25.00% | 2.47% | -62.07% | -480.37% | 173.01% |
| Change in YoY Net Profit Growth (%) | 0.00% | 317.22% | -206.24% | -76.76% | 42.55% | -31.16% | 41.11% | -22.53% | -64.55% | -418.30% | 653.38% |
Glenmark Life Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 5% |
| 3 Years: | 3% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 12% |
| 3 Years: | 6% |
| TTM: | 159% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 33% |
| 3 Years: | 74% |
| 1 Year: | 16% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | -1% |
| 3 Years: | -10% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 3:36 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 131 | 140 | 120 | 97 | 94 | 81 | 83 | 86 | 92 | 115 | 57 | 92 |
| Inventory Days | 191 | 247 | 249 | 299 | 244 | 244 | 211 | 230 | 208 | 203 | 208 | 254 |
| Days Payable | 279 | 379 | 308 | 243 | 225 | 241 | 210 | 226 | 190 | 172 | 210 | 216 |
| Cash Conversion Cycle | 43 | 8 | 61 | 152 | 113 | 85 | 84 | 90 | 110 | 147 | 56 | 129 |
| Working Capital Days | 62 | 47 | 51 | 125 | 99 | 64 | 54 | 67 | 65 | 141 | -2 | 44 |
| ROCE % | 15% | 16% | 19% | 21% | 15% | 15% | 14% | 15% | 16% | 10% | 12% | 19% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid-Cap Opportunities Fund - Regular Plan | 8,778,612 | 1.62 | 1212.5 | N/A | N/A | N/A |
| Mirae Asset Large & Midcap Fund | 3,313,007 | 1.21 | 457.59 | N/A | N/A | N/A |
| Mirae Asset ELSS Tax Saver Fund | 2,689,916 | 1.5 | 371.53 | 2,550,247 | 2025-06-29 09:52:48 | 5.48% |
| Invesco India Contra Fund | 1,662,235 | 1.27 | 229.59 | 1,510,869 | 2025-06-29 09:52:49 | 10.02% |
| Mirae Asset Midcap Fund | 1,472,836 | 1.32 | 203.43 | N/A | N/A | N/A |
| Invesco India Mid Cap Fund | 1,323,818 | 3.02 | 182.85 | 1,173,731 | 2025-06-29 09:52:49 | 12.79% |
| Invesco India Large & Mid Cap Fund | 1,205,107 | 2.46 | 166.45 | N/A | N/A | N/A |
| Kotak Equity Arbitrage Fund - Regular Plan | 1,127,100 | 0.25 | 155.68 | N/A | N/A | N/A |
| HDFC Manufacturing Fund | 1,100,000 | 1.3 | 151.93 | N/A | N/A | N/A |
| Invesco India Arbitrage Fund | 1,021,150 | 0.7 | 141.04 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 |
| Diluted EPS (Rs.) | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 |
| Cash EPS (Rs.) | 54.33 | -30.18 | 35.04 | 52.46 | 50.10 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 313.60 | 278.09 | 348.70 | 334.48 | 250.36 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 313.60 | 278.09 | 348.70 | 334.48 | 250.36 |
| Revenue From Operations / Share (Rs.) | 472.08 | 418.62 | 460.36 | 436.08 | 387.85 |
| PBDIT / Share (Rs.) | 87.36 | 72.13 | 91.97 | 88.14 | 75.65 |
| PBIT / Share (Rs.) | 70.13 | 51.50 | 70.31 | 70.89 | 59.93 |
| PBT / Share (Rs.) | 49.58 | 1.29 | 30.78 | 51.08 | 48.99 |
| Net Profit / Share (Rs.) | 37.11 | -50.80 | 13.37 | 35.21 | 34.38 |
| NP After MI And SOA / Share (Rs.) | 37.11 | -53.21 | 10.53 | 33.37 | 34.38 |
| PBDIT Margin (%) | 18.50 | 17.22 | 19.97 | 20.21 | 19.50 |
| PBIT Margin (%) | 14.85 | 12.30 | 15.27 | 16.25 | 15.45 |
| PBT Margin (%) | 10.50 | 0.30 | 6.68 | 11.71 | 12.63 |
| Net Profit Margin (%) | 7.86 | -12.13 | 2.90 | 8.07 | 8.86 |
| NP After MI And SOA Margin (%) | 7.86 | -12.71 | 2.28 | 7.65 | 8.86 |
| Return on Networth / Equity (%) | 11.83 | -19.13 | 3.13 | 10.36 | 13.73 |
| Return on Capital Employeed (%) | 19.62 | 17.01 | 13.84 | 16.13 | 14.83 |
| Return On Assets (%) | 6.52 | -10.45 | 1.53 | 5.51 | 6.21 |
| Long Term Debt / Equity (X) | 0.05 | 0.00 | 0.40 | 0.28 | 0.55 |
| Total Debt / Equity (X) | 0.24 | 0.12 | 0.45 | 0.40 | 0.66 |
| Asset Turnover Ratio (%) | 0.87 | 0.70 | 0.71 | 0.42 | 0.42 |
| Current Ratio (X) | 1.56 | 1.28 | 1.96 | 1.77 | 1.75 |
| Quick Ratio (X) | 1.05 | 0.84 | 1.37 | 1.23 | 1.21 |
| Inventory Turnover Ratio (X) | 4.81 | 1.15 | 1.31 | 1.85 | 1.85 |
| Dividend Payout Ratio (NP) (%) | 6.73 | -4.69 | 23.73 | 7.49 | 7.27 |
| Dividend Payout Ratio (CP) (%) | 4.60 | -7.66 | 7.76 | 4.93 | 4.99 |
| Earning Retention Ratio (%) | 93.27 | 104.69 | 76.27 | 92.51 | 92.73 |
| Cash Earning Retention Ratio (%) | 95.40 | 107.66 | 92.24 | 95.07 | 95.01 |
| Interest Coverage Ratio (X) | 11.90 | 3.94 | 7.42 | 8.34 | 6.04 |
| Interest Coverage Ratio (Post Tax) (X) | 7.86 | -0.80 | 4.27 | 5.21 | 3.62 |
| Enterprise Value (Cr.) | 43947.27 | 26350.45 | 16364.27 | 15087.86 | 16656.12 |
| EV / Net Operating Revenue (X) | 3.30 | 2.23 | 1.26 | 1.23 | 1.52 |
| EV / EBITDA (X) | 17.83 | 12.95 | 6.31 | 6.07 | 7.80 |
| MarketCap / Net Operating Revenue (X) | 3.26 | 2.29 | 1.01 | 1.01 | 1.20 |
| Retention Ratios (%) | 93.26 | 104.69 | 76.26 | 92.50 | 92.72 |
| Price / BV (X) | 4.91 | 3.44 | 1.38 | 1.37 | 1.86 |
| Price / Net Operating Revenue (X) | 3.26 | 2.29 | 1.01 | 1.01 | 1.20 |
| EarningsYield | 0.02 | -0.05 | 0.02 | 0.07 | 0.07 |
After reviewing the key financial ratios for Glenmark Life Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -53.22 (Mar 24) to 37.11, marking an increase of 90.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -53.22 (Mar 24) to 37.11, marking an increase of 90.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 54.33. This value is within the healthy range. It has increased from -30.18 (Mar 24) to 54.33, marking an increase of 84.51.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.60. It has increased from 278.09 (Mar 24) to 313.60, marking an increase of 35.51.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.60. It has increased from 278.09 (Mar 24) to 313.60, marking an increase of 35.51.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 472.08. It has increased from 418.62 (Mar 24) to 472.08, marking an increase of 53.46.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 87.36. This value is within the healthy range. It has increased from 72.13 (Mar 24) to 87.36, marking an increase of 15.23.
- For PBIT / Share (Rs.), as of Mar 25, the value is 70.13. This value is within the healthy range. It has increased from 51.50 (Mar 24) to 70.13, marking an increase of 18.63.
- For PBT / Share (Rs.), as of Mar 25, the value is 49.58. This value is within the healthy range. It has increased from 1.29 (Mar 24) to 49.58, marking an increase of 48.29.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -50.80 (Mar 24) to 37.11, marking an increase of 87.91.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -53.21 (Mar 24) to 37.11, marking an increase of 90.32.
- For PBDIT Margin (%), as of Mar 25, the value is 18.50. This value is within the healthy range. It has increased from 17.22 (Mar 24) to 18.50, marking an increase of 1.28.
- For PBIT Margin (%), as of Mar 25, the value is 14.85. This value is within the healthy range. It has increased from 12.30 (Mar 24) to 14.85, marking an increase of 2.55.
- For PBT Margin (%), as of Mar 25, the value is 10.50. This value is within the healthy range. It has increased from 0.30 (Mar 24) to 10.50, marking an increase of 10.20.
- For Net Profit Margin (%), as of Mar 25, the value is 7.86. This value is within the healthy range. It has increased from -12.13 (Mar 24) to 7.86, marking an increase of 19.99.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.86. This value is below the healthy minimum of 8. It has increased from -12.71 (Mar 24) to 7.86, marking an increase of 20.57.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.83. This value is below the healthy minimum of 15. It has increased from -19.13 (Mar 24) to 11.83, marking an increase of 30.96.
- For Return on Capital Employeed (%), as of Mar 25, the value is 19.62. This value is within the healthy range. It has increased from 17.01 (Mar 24) to 19.62, marking an increase of 2.61.
- For Return On Assets (%), as of Mar 25, the value is 6.52. This value is within the healthy range. It has increased from -10.45 (Mar 24) to 6.52, marking an increase of 16.97.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.05, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.12 (Mar 24) to 0.24, marking an increase of 0.12.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.87. It has increased from 0.70 (Mar 24) to 0.87, marking an increase of 0.17.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has increased from 1.28 (Mar 24) to 1.56, marking an increase of 0.28.
- For Quick Ratio (X), as of Mar 25, the value is 1.05. This value is within the healthy range. It has increased from 0.84 (Mar 24) to 1.05, marking an increase of 0.21.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.81. This value is within the healthy range. It has increased from 1.15 (Mar 24) to 4.81, marking an increase of 3.66.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 6.73. This value is below the healthy minimum of 20. It has increased from -4.69 (Mar 24) to 6.73, marking an increase of 11.42.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 4.60. This value is below the healthy minimum of 20. It has increased from -7.66 (Mar 24) to 4.60, marking an increase of 12.26.
- For Earning Retention Ratio (%), as of Mar 25, the value is 93.27. This value exceeds the healthy maximum of 70. It has decreased from 104.69 (Mar 24) to 93.27, marking a decrease of 11.42.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.40. This value exceeds the healthy maximum of 70. It has decreased from 107.66 (Mar 24) to 95.40, marking a decrease of 12.26.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.90. This value is within the healthy range. It has increased from 3.94 (Mar 24) to 11.90, marking an increase of 7.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.86. This value is within the healthy range. It has increased from -0.80 (Mar 24) to 7.86, marking an increase of 8.66.
- For Enterprise Value (Cr.), as of Mar 25, the value is 43,947.27. It has increased from 26,350.45 (Mar 24) to 43,947.27, marking an increase of 17,596.82.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.30. This value exceeds the healthy maximum of 3. It has increased from 2.23 (Mar 24) to 3.30, marking an increase of 1.07.
- For EV / EBITDA (X), as of Mar 25, the value is 17.83. This value exceeds the healthy maximum of 15. It has increased from 12.95 (Mar 24) to 17.83, marking an increase of 4.88.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has increased from 2.29 (Mar 24) to 3.26, marking an increase of 0.97.
- For Retention Ratios (%), as of Mar 25, the value is 93.26. This value exceeds the healthy maximum of 70. It has decreased from 104.69 (Mar 24) to 93.26, marking a decrease of 11.43.
- For Price / BV (X), as of Mar 25, the value is 4.91. This value exceeds the healthy maximum of 3. It has increased from 3.44 (Mar 24) to 4.91, marking an increase of 1.47.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has increased from 2.29 (Mar 24) to 3.26, marking an increase of 0.97.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.02, marking an increase of 0.07.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Glenmark Life Sciences Ltd:
- Net Profit Margin: 7.86%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 19.62% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.83% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.86
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.05
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 38.7 (Industry average Stock P/E: 55.95)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.24
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.86%